Otros idiomas Alterity Therapeutics Limited

Acciones

ATH

AU0000043945

Mercado cerrado - Australian S.E. Otros sitios de cotización 08:10:18 01/07/2024			Varia. Cinco días.	Varia. 1 de enero.
0,005 ^AUD	+25,00 %		+11,11 %	-28,57 %

08/05	El Comité de Supervisión de Datos de Fase 2 de Alterity Therapeutics recomienda continuar el ensayo clínico según lo previsto tras su tercera revisión	CI
29/04	Alterity Therapeutics Limited presenta nuevos datos que demuestran el potencial de ATH434 para tratar enfermedades neurodegenerativas raras	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	08/05
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	08/05
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	29/04
ADRs End Lower, Purple Biotech Ltd. Declines 29%	16/04
ADRs End Lower, Leju Holdings Ltd. Declines 72%	12/04
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	11/04
ADRs Close Lower; VIA Optronics AG Declines 30%	10/04
Top Midday Gainers	10/04
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund	26/03
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	26/03
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund	26/03
Genetic Technologies Appoints CFO	25/03
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	15/03
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	28/02
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	23/02
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06/02
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06/02
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	06/02
Alterity Therapeutics Completes Securities Purchase Plan	02/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Alterity Therapeutics Limited

Acciones

ATH

AU0000043945

Otros idiomas

Filtros